Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iSpecimen (ISPC) EBT (2020 - 2025)

Historic EBT for iSpecimen (ISPC) over the last 6 years, with Q3 2025 value amounting to -$2.8 million.

  • iSpecimen's EBT fell 6534.49% to -$2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.3 million, marking a year-over-year decrease of 2674.53%. This contributed to the annual value of -$12.9 million for FY2024, which is 1855.21% down from last year.
  • iSpecimen's EBT amounted to -$2.8 million in Q3 2025, which was down 6534.49% from -$1.8 million recorded in Q2 2025.
  • iSpecimen's 5-year EBT high stood at -$1.4 million for Q2 2021, and its period low was -$6.0 million during Q4 2024.
  • Over the past 5 years, iSpecimen's median EBT value was -$2.2 million (recorded in 2024), while the average stood at -$2.5 million.
  • Its EBT has fluctuated over the past 5 years, first crashed by 70058.43% in 2021, then surged by 4494.69% in 2025.
  • iSpecimen's EBT (Quarter) stood at -$2.0 million in 2021, then fell by 6.51% to -$2.2 million in 2022, then crashed by 30.96% to -$2.8 million in 2023, then crashed by 111.96% to -$6.0 million in 2024, then surged by 52.79% to -$2.8 million in 2025.
  • Its last three reported values are -$2.8 million in Q3 2025, -$1.8 million for Q2 2025, and -$1.6 million during Q1 2025.